Australia's most trusted
source of pharma news
Wednesday, 20 May 2026
Posted 20 May 2026 AM
The progressive pulmonary fibrosis (PFF) market is forecast to hit US$2.7 billion across the seven major markets (7MM) by 2035, driven by the launch of five new drugs.
In 2025, the PFF market was dominated by a single drug, Boehringer Ingelheim’s Ofev, which is considered the gold standard disease modifying treatment.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.